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ABSTRACT
Rituximab is a chimeric monoclonal antibody
directed at the CD20 molecule on the surfaces
of some but not all B cells. It depletes almost all
peripheral B cells, but other niches of B cells are
variably depleted, including synovium. Its
mechanism of action in rheumatoid arthritis
(RA) is only partially understood. Rituximab
was efficacious in clinical trials of patients with
RA, including those who are methotrexate
naı¨ve, those with an incomplete response to
methotrexate, and those with an incomplete
response to tumor necrosis factor inhibitors.
The need for a concomitant traditional
disease-modifying drug, the optimal dose of
rituximab, and the optimal interval for
retreatment remain somewhat uncertain.
Rituximab seems to be most efficacious in
seropositive patients and those with an
incomplete response to only one tumor
necrosis factor inhibitor. Rituximab has a
reasonable safety profile, with a small risk of
serious infectious events, which is stable over
time and repeat courses. Opportunistic
infections are rare. Reactivation of hepatitis B
remains a concern. The possible association of
rituximab and progressive multifocal
leukoencephalopathy may still require
vigilance. Malignancies and cardiovascular
events do not appear to be increased. Infusion
reactions are more likely with the initial
infusion, and are usually mild. Rituximab may
cause hypogammaglobulinemia, but any risk of
subsequent risk of increased infectious events is
not yet well established. Before initiating
rituximab, patient screening for
hypersensitivity to murine proteins, infections,
congestive heart failure, pregnancy, and
hypogammaglobulinemia is imperative.
Vaccinations should be administered prior to
treatment whenever possible. Rituximab has
been a significant addition to the
rheumatologists’ armamentarium for the
treatment of RA.
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INTRODUCTION
Rituximab remains a unique therapeutic option
for the treatment of rheumatoid arthritis. There
is now a rich literature regarding its efficacy and
safety. Questions remain, however, about its
exact mechanism of action in RA, the most
appropriate dosing schedule, and which RA
patients might benefit the most from its use.
All of these aspects of rituximab for RA are
reviewed in this article.
MECHANISMS OF ACTION
Rituximab is a monoclonal antibody directed at
the CD20 molecule on the surfaces of some B
cells. It is a chimeric product consisting of
approximately 20% mouse and 80% human
protein. Rituximab depletes mature B cells and
pre-B cells through memory B cell stages, but
stem cells, pro-B cells, terminally differentiated
plasma cells, and plasmablasts do not express
CD20 and are not depleted [1, 2]. Intravenous
rituximab in RA patients results in almost
complete depletion of peripheral B cells and
variable depletion of B cells in synovium and
other sites such as lymphoid tissue and bone
marrow [2, 3]. Clinical response correlates to
some degree with synovial tissue B cell
depletion and perhaps with peripheral B cell
depletion [3–6]. Reconstitution of B cells post
rituximab results in immature, naı¨ve B cells, but
in many patients it leads to relapse of clinical
disease [3]. Rituximab depletes B cells by several
mechanisms, including mediation of
antibody-dependent cellular cytotoxicity,
complement-dependent cytotoxicity, and B
cell apoptosis [2]. Precisely how B cell
depletion results in clinical efficacy in RA is
incompletely understood, but the effects may
be mediated via B cell antigen presentation
ability, B cell production of cytokines, and B cell
production of autoantibodies such as
rheumatoid factor [1, 2].
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APPROVAL
Rituximab has been approved by the US Food
and Drug Administration and the European
Medicines Agency in Europe for the treatment
of RA in patients with an incomplete response
or intolerance to tumor necrosis inhibitors
(TNFi). It is licensed as two intravenous 1 gm
infusions separated by 2 weeks with
concomitant methotrexate (MTX) and with
intravenous corticosteroid premedication [7].
EFFICACY
Rituximab has been established as efficacious
and safe in RA in combination with MTX and
disease-modifying antirheumatic drugs
(DMARDs) [8–14] The rituximab-MTX
combination was initially demonstrated to be
superior than either drug as monotherapy
(DANCER), and premedication with 100 mg of
methylprednisolone did not affect the
achievement of the primary endpoint [9]. In
two subsequent trials (SERENE, MIRROR),
rituximab plus MTX was superior to
methotrexate plus placebo, and two doses of
1000 mg were marginally clinically different
100 Rheumatol Ther (2015) 2:99–111
than two doses of 500 mg [10, 11]. Both
rituximab doses were similar to MTX ?
placebo with regards to safety.
In patients with an incomplete response to
TNFi, rituximab ?MTX has also been
established as safe and efficacious [12–14]. In
the REFLEX trial, the rituximab-treated group
(2 9 1000 mg) was clinically superior at week
24, and a significant percentage of
placebo-treated patients were capable of being
rescued by subsequent rituximab [12]. In
addition, subsequent courses of rituximab
were also safely and efficaciously administered.
At 2 years, radiographic progression was
significantly reduced in the rituximab-treated
group compared to the placebo group [13]. In a
later trial (SUNRISE), rituximab was clinically
superior to placebo, and retreatment at
6 months was superior to a single course at
1 year [14].
A phase 3 trial (IMAGE) also demonstrated
the efficacy of rituximab in early RA patients
who were MTX-naı¨ve [15]. Rituximab was used
in 2 9 500 and 2 9 1000 mg doses in this trial,
and although clinical efficacy was similar, a
significant reduction in radiographic damage
was only seen in the latter treatment group at
1 year. At 2 years, however, the lower-dose
group also demonstrated a reduction in
radiographic damage compared to the placebo
group [16]. The study was insufficiently
powered to differentiate statistically between
the two rituximab doses.
Rituximab has been studied in combination
with TNFi agents, and the numerical risk of
serious adverse events was only slightly
increased, but without a significant increase in
efficacy [17].
Rituximab has been combined with
DMARDs other than MTX to achieve clinical
efficacy [18]. Certainly leflunomide seems to be
a viable alternative [18, 19].
Although rituximab is approved in
combination with MTX, rituximab was used as
monotherapy in the original phase 2 trial, and
the response was superior to placebo for ACR20
responses but not for higher-level responses. A
later study also found rituximab monotherapy
to be efficacious, but the authors concluded that
it should only be used for selected patients [19].
A large registry review found that rituximab
combined with MTX or leflunomide was
superior to rituximab monotherapy, although
another registry found monotherapy to be
reasonably efficacious [18, 20]. Rituximab
monotherapy is therefore not usually
recommended except for exceptional
circumstances.
Given the data cited from the DANCER,
SERENE, and IMAGE trials, there has been
controversy over the optimal rituximab dose.
While it appeared that the 2 9 1000 mg and
2 9 500 mg doses may be equivalent with
respect to improvement in signs and
symptoms, the 2 9 1000 mg dose showed
better ‘‘high hurdle’’ outcomes. The
2 9 1000 mg rituximab dose demonstrated a
more rapid inhibition of radiographic damage
compared to the lower dose, and there was also
a trend for more radiographic inhibition with
the higher dose. To date, there are no data
concerning the ability of the 2 9 500 mg dose to
inhibit radiographic progression in
TNF-inadequate responders. Bredemeier et al.
conducted a meta-analysis of four rituximab
studies which utilized the two doses and
concluded that there were no significant
differences in the clinical responses. There
were limitations in the analysis, however; the
main being the comparison of heterogeneous
populations, including populations in which
rituximab is not licensed for use: in MTX-naı¨ve
patients. Also, in this analysis, some of the
included studies were only powered to detect a
Rheumatol Ther (2015) 2:99–111 101
difference between the rituximab dose and
placebo, not between the two drug doses, and
the results of the non-inferiority analyses were
not consistent for all outcomes [21]. A large
registry review was somewhat less certain about
any differences between doses, but in an
incisive editorial there was a call for more
studies to address the appropriate rituximab
dose issue [22, 23]. Whether or not the higher
dose needs to be continued throughout all
treatment courses once a targeted response is
achieved is also uncertain. With regards to the
question of retreatment dosing, an open label
prospective non-inferiority study by Mariette
et al. revealed that, in patients who achieved a
EULAR good/moderate response 6 months after
an initial 1000 mg 9 2 rituximab dose,
retreatment with a single 1000 mg rituximab
dose was non-inferior to retreatment with a
1000 mg dose 9 2 dose regimen [24].
A number of studies have demonstrated that
rituximab is more efficacious in seropositive
(rheumatoid factor (RF) and anti-citrullinated
peptide antibody (ACPA) RA patients [25–27].
Data from large registries also suggest superior
clinical efficacy [28–32]. In the REFLEX trial, a
response was seen in seropositive (rheumatoid
factor) and to a lesser extent in seronegative
patients, but a significant reduction in
radiographic patients was only seen in the
seropositive group [11, 30]. In the REFLEX
SERENE, and IMAGE studies, seropositivity for
RF and ACPA was associated with a superior
clinical response to rituximab [31]. A vigorous
analysis of the question of antibody status and
response was carried out in a meta-analysis of
four trials (REFLEX, DANCER, IMAGE, and
SERENE) by Isaacs et al. [25]. When a
fixed-effect model was used, the results
indicated a benefit with rituximab in
seropositive patients compared to seronegative
patients, but with a modest reduction in
DAS28-ESR of 0.35 units, although
heterogeneous indices suggested significant
uncertainty in the overall-effect model.
Response to rituximab has also been reported
to be more efficacious in patients who have
failed only one TNFi, as opposed to those who
have failed more than one [28, 30]. A number of
studies have attempted to compare the use of
rituximab in TNFi-incomplete responders versus
switching to another TNFi, and although the
results of many of these studies favor rituximab,
they have not all been large, blinded, or direct
comparisons and have not led to an accepted
consensus [32–37]. Given the pending patent
expiration, any further, more rigorous studies
are unlikely to be conducted.
Biomarkers and genetic markers have also
been postulated to affect the clinical response to
rituximab. Among others, these include
Fc-gamma receptor type IIIA polymorphism,
promoter polymorphism of the B-cell
activation factor gene, baseline numbers of
CD27? memory cells, and levels of B cell
chemokines [38–41]. B cell subset numbers
have been reported to predict responsiveness
to rituximab, but whether or not any of these
factors will ultimately be widely available or
practical remains to be determined [42, 43].
RETREATMENT WITH RITUXIMAB
In clinical trials (SERENE, MIRROR, DANCER),
repeat rituximab dosing was allowed every
6 months [9–11]. Typical clinical responses
from rituximab are usually seen 3–4 months
after the initial infusions, although the
concomitant corticosteroids may provide a
very early, transient effect [7]. The duration of
the effect is quite variable, so the optimal
timing for retreatment is difficult to predict.
Repopulation of B cells after rituximab usually
requires 6–9 months, but is also variable [1, 4].
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The US package insert for rituximab suggests
that rituximab can be given not sooner than
every 4 months according to clinical evaluation.
Several retreatment options have been studied.
A review of retreated patients from the clinical
trials suggested that the fixed-interval (24 week)
treat to target strategy was superior to one
which retreated patients at the discretion of the
physician (prn) [44]. In this retrospective
pooled analysis, baseline disease characteristics
were thought to be generally well balanced, but
those patients receiving prn retreatment were
more likely to have established RA with a
median 8.5 years of disease and were more
likely to be TNF-inadequate responders, while
those patients retreated using a treat to target
approach were more likely to have a shorter
disease duration with a median of 3.6 years of
disease and to be biologic-naı¨ve. That the
differences between the two groups may have
influenced the results remains a significant
possibility. A prospective study demonstrated
that rituximab retreatment was deemed
necessary at around 8 months [45]. The latest
European consensus statement suggests that
retreatment in initial responders should be
considered at 24 weeks in patients who do not
achieve low disease activity or remission, and
that it should be delayed otherwise until disease
activity flares [7].
Whether or not initial nonresponders should
be retreated remains somewhat uncertain [46,
47]. While data from the SUNRISE study
demonstrated a low response overall to repeat
treatment in initial rituximab nonresponders,
repeat treatment was superior to a single course
[14]. Analysis of data from the MIRROR study
demonstrated that 46% of patients failing to
achieve an ACR20 response after initial
treatment achieved at least an ACR20 response
at 48 weeks following their second treatment
course [11]. In the analysis by Vital et al., a
proportion of the patients not responding to an
initial rituximab course exhibited improvement
following an additional course [46]. These data
suggest that an additional course of treatment
within 24 weeks might be carefully considered
in initial rituximab nonresponders, in contrast
to the published guidelines which state that
alternative treatment agents should probably be
considered in initial nonresponders [7].
SAFETY OF RITUXIMAB
In two of the clinical trials, a numerically higher
rate of serious inferctions, but not opportunistic
infections including tuberculosis, was reported
in patients receiving the 2 9 1000 mg dose
compared to placebo, 4.7 compared to 3.2/100
patient years in DANCER and 5.2 compared to
3.7 patient years in REFLEX [8, 11]. In the
IMAGE trial, however, the rate of serious
infections was lower in both of the rituximab
treatment arms compared to placebo [15]. In
addition, a meta-analysis did not report an
increased risk of serious infections in
rituximab-treated patients compared to
placebo-treated patients [48]. Data from a large
French registry observed a slightly increased
rate of serious infections in rituximab-treated
patients in the first 6 months of treatment,
comparable to the rate reported in randomized
clinical trials [49]. With regards to serious
infections requiring hospitalization, a study
concluded that the rate of such infections
with rituximab was comparable to that seen
with the TNFi infliximab [50].
Van Vollenhoven et al. have recently
reported a pooled analysis of the long-term
safety of rituximab in global clinical trials over
9.5 and then 11 years [51, 52]. The initial
published data included 3194 patients and
11,962 patient years. Overall, infections
(in[5%) reported in the rituximab-treated
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patients were upper respiratory infections,
nasopharyngitis, urinary tract infections,
bronchitis, sinusitis, diarrhea, and
gastroenteritis. The most common serious
infection was pneumonia, with an overall
serious infection rate of 3.94/100 patient years,
and this was comparable to the rate of patients
treated with MTX ? placebo at 3.79/100 patient
years. Importantly, the risk of serious infections
was stable over time, even with multiple courses
of treatment. There were two cases of
tuberculosis (TB), no cases of extrapulmonary
TB, no cases of atypical TB, and other
opportunistic infections were very rare. There
were no cases of hepatitis B reactivation, but
one case of de novo hepatitis B. Rates of herpes
zoster infection were 9.0/1000 patient-years,
but this was comparable to the
MTX ? placebo-treated patients (11.7/1000
patient-years) and the general RA population
(11.5 patient-years).
Another paper reported three cases of TB and
five cases of non-TB mycobacterial infections in
a survey of rituximab-treated RA patients [53]. A
previously mentioned report included patients
with TB treated with rituximab without
reactivation [49]. A recent study of 56
rituximab-treated patients at high risk for TB
did not report any reactivation [54]. The risk of
hepatitis C reactivation seems uncertain [55].
Progressive multifocal leukoencephalitis
(PML) is a progressive infection caused by the
JC virus, and cases of PML have been reported in
RA patients treated with rituximab [56–59]. A
recent review in abstract form cited a total of 11
cases of PML in RA patients treated with all
biologics, with rituximab being the most
recently administered biologic in most of these
[58]. In many of the reported cases, there had
been previous treatment with
immunosuppressive medications. The true
incidence of PML in RA is still uncertain, but a
large registry reported on 66,278 RA patients,
with a rate of PML of 1.0/100,000 person-years
as compared to that for the general population,
0.3/100,000 person-years [59]. In the European
consensus statement regarding the use of
rituximab in RA, the risk of PML was judged as
small, but without an identified risk profile for
the development of PML, vigilance was advised
[7]. Given the relative paucity of PML cases in
RA despite the increasing numbers of patients
receiving rituximab in surveillance databases,
the concern regarding PML may be waning.
The risk of malignancy does not appear to be
increased in the clinical trials with very small
numbers of cases, although patients with a
known previous malignancy are usually
excluded and the trials are of relatively short
duration. In the pooled analysis, rituximab was
not associated with an increased risk of any
malignancy when compared to age- and
sex-matched standard incidence ratios [51].
The calculated incidence rate of any
malignancy was 0.69/100 patient-years. The
most common solid malignancy was breast
cancer. In addition, there was no evidence of
an increased risk of malignancy with cumulative
exposure to rituximab. Other reviews have also
not found an increase in malignancies [60, 61].
A French registry review also reported no
significant increase in malignancies in a
rituximab-treated RA patient cohort [62]. A
recent comparative effectiveness study
comparing the potential risk of cancer across
biologic and non-biologic DMARDs reported
that the risk of any cancer with rituximab was
similar to that with methotrexate [63]. In a
recent abstract, the German registry reported
that RA patients with a history of lymphoma,
solid malignancies, or skin cancer do not have
higher rates of recurrence when treated with
rituximab in comparison to non-biologic
DMARDs [64].
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With regards to cardiovascular risk, which is
increased in patients with RA regardless of
treatment, myocardial infarction was the most
frequent cardiovascular event reported in the
pooled analysis of long-term safety data [47].
The event rate was 0.41/100 patient-years
compared to 0.27/100 patient-years in the
MTX ? placebo-treated patients. This rate was
similar to that reported in other RA patients
treated with DMARDS and TNFi [65, 66]. The
risk of stroke was similar in both groups and
also similar to other published data [67].
Currently, there are no data showing that
rituximab is associated with deterioration of
cardiac function. Patients with significant
uncontrolled cardiac disease were excluded
from the major clinical trials in RA because of
concerns about potential cardiac complications
associated with infusion reactions.
Infusion-related reactions (IRR) have been
reported in all of the clinical trials of rituximab
in RA. In the pooled analysis of long-term safety,
the rate of IRRwas 23%during thefirst infusionof
the first course and decreased with each
subsequent infusion [51]. Most of the IRR were
judged as mild to moderate and were rarely
serious (\1%). The most common reactions
included headache, pruritis, throat irritation,
flushing, rash, changes in blood pressure, and
fever. The DANCER trial included premedication
with 100 mg of intravenousmethylprednisolone,
whichwas concluded to reduce the frequency and
severity of the initial infusion reactions without
contributing to the primary clinical endpoint [8].
This premedication isnowpart of the approval for
each cycle of rituximab, although whether or not
it is required for all late cycles has not been
determined [7]. The routine use of antihistamines
and/or paracetamol is not required, but may be
useful for mild IRR [7].
Although rituximab does not affect
immunoglobulin-secreting plasma cells,
repeated courses of rituximab in RA have
caused hypoglobulinemia [51]. A registry
review demonstrated that a low IgG level before
rituximab treatment was a risk factor for serious
infections [49]. In the clinical trials, a low IgG
level was an exclusion criterion and prohibited
trial entry, but low immunoglobulins, IgM[
IgG, were observed. An analysis of three
randomized controlled trials of rituximab
included 1039 patients, and 10.3% had a low
IgM at week 24, but this increased to 18.5% with
a second cycle and 23.5% after a third cycle of
therapy [68]. Similarly, 1.5% had a low IgG at
week 24; 4.3% and 5.9% with subsequent cycles
of therapy. Despite these findings, the rates of
serious infections were 5.6 and 4.8/100
patient-years for IgM and IgG respectively, and
the rate in patients with normal
immunoglobulins was comparable at 4.7/100
patient-years [6]. In the pooled analysis of
long-term rituximab safety, 22.4% developed a
low IgM level and 3.5% a low IgG level [51]. No
increases in overall infection rates were observed
in patients during or after the development of
low IgMor IgG levels, but for IgG these rates were
higher than in patients who never developed a
low IgG.With the small numbers of patientswith
low IgG levels, no placebo comparator, and
difficulties determining when immunoglobulin
levels decreased, analysis of the datawas thought
to be limited [51]. The European guidelines
regarding rituximab treatment suggest
monitoring of immunoglobulin levels, with
close monitoring for infection in those patients
with low IgG levels [7].
ANTI-RITUXIMAB ANTIBODIES
In the randomized, controlled trials, the
incidence of human anti-chimeric antibodies
(HACA) varied from 2.7% to 7.1% [9–15]. In the
pooled analysis of long-term rituximab safety,
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11% of rituximab-treated patients were found to
have HACAs during at least one visit [51]. These
and other studies have found no relationship
between HACA and the dose of rituximab
administered, any specific clinical
manifestations, the ability to deplete B cells,
the frequency of infusion reactions, the clinical
efficacy of the initial dosing, or the efficacy of
retreatment [51, 68, 69].
Biologic DMARD Therapy Post-Rituximab
In a study concerning patients in whom an
insufficient response was obtained with
rituximab, switching from rituximab to a TNFi
was relatively safe and not associated with an
increase in infections [70]. In this study, the
TNFi were initiated at least 4 months after
rituximab, and the rate of serious infections
was similar to that expected when TNFi are
initiated in biologic-naı¨ve DMARD RA patients.
Similarly, the pooled analysis of long-term
rituximab safety data concluded that the use
of subsequent biologics was not associated with
an increase in the serious infection rate [51].
Other Treatment Considerations
Given all of these safety concerns, prior to
initiating rituximab in RA patients, a careful
medical history and physical examination
should be undertaken to determine potential
contraindications. Some of these include
hypersensitivity to murine proteins, serious
active infection, significant congestive heart
failure, and pregnancy [7]. In addition to
routine laboratory testing, baseline
immunoglobulin levels should be measured,
since low IgG levels are associated with a
higher risk of infection, and the use of
rituximab in patients with existing
hypogammaglobulinemia should be
considered with caution or avoided [7].
Hepatitis B and C serologies should be
undertaken, because reactivation of hepatitis B
surface Ag negative but hepatitis B core Ab
positive disease has been rarely reported [71,
72]. Those patients who are HBsAg and anti-HBc
negative should consider vaccination before
rituximab is initiated, and those patients who
are HBsAg and/or anti-HBc positive should not
be given rituximab or they should be referred to
a hepatologist for consideration of prophylactic
treatment before rituximab is considered.
HBsAg-negative but anti-HBc-positive patients
should have HBV DNA titers and, if
undetectable, rituximab might be considered,
particularly after a hepatologist administers
prophylactic antiviral therapy and with close
monitoring of HBV DNA levels [7]. With regards
to hepatitis C (HCV), rituximab has been used
successfully to treat HCV-induced
cryoglobulinemia, suggesting its safety with
HCV. Rheumatologists should screen for HCV
only to refer patients to hepatologists for
treatment using interferon-free regimens [55].
Patients who have been treated with TNFi
should have previously been evaluated for TB,
but due to the observation that there is no
evidence for an increased frequency of TB in RA
patients treated with rituximab, screening
patients for tuberculosis is not currently
thought to be necessary [7].
Vaccinations in RA patients should be
considered before rituximab, including
pneumococcal, influenza, tetanus toxoid, and
hepatitis B, and these are recommended at least
4 weeks before the initiation of rituximab [7].
Diminished humoral responses to influenza and
pneumococcus have been reported in RA
patients on rituximab ?methotrexate, so
immunization while on rituximab therapy
may not be effective [73–75]. Live vaccines are
not recommended.
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Lastly, as currently recommended, rituximab
infusion requires 4.25 h for the initial infusion
and 3.25 h for subsequent infusions. This
regimen is based on the rituximab usage in
non-Hodgkins lymphoma, where the incidence
of IRR is much higher than that observed in RA
[76]. Long infusion times and frequent infusion
rate changes are not only inconvenient but
increase infusion center costs. Several studies
have attempted to increase the rate of rituximab
infusion after the initial infusion, with reported
success [76–80]. In a recent study, infusion over
2 h was well tolerated and not associated with
an increased rate of IRR [76]. Rapid infusion
protocols, however, require further testing
before general acceptance will be achieved.
CONCLUSION
Rituximab has been a significant addition to the
shortlist of biologic agents approved for the
treatment of RA. It has a unique mechanism of
action, it has been established as relatively safe,
and the details regarding screening, dosing, and
follow-up are becoming better understood.
Rituximab is an important option for selected
RA patients, and is most effective in those who
are seropositive and have been exposed to one
TNFi. As with all biologics for RA, further
information regarding the safety of rituximab
over longer periods of time will be critical.
Future studies will hopefully determine exactly
where rituximab will be placed in the evolving
treatment paradigm for rheumatoid arthritis.
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